UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~March 31, ~~2010~~ 2011

TIENS BIOTECH GROUP (USA), INC.

(Exact name of registrant as specified in its charter)


Delaware	001-32477	75-2926439
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

No. 617, ~~Yuanquan~~Xinyuan ~~Road~~Rd., Wuqing New- Tech Industrial Park, Tianjin, China 301700

(Address of principal executive offices)

Registrant'’s telephone number, including area code:（ (011) 86）-22-8213-~~7335~~7914

~~Not applicable~~_______________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting ~~material~~materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~1

~~Effective as~~Item ~~of December 31, 2010, Howard Balloch resigned from his position as Director of Tiens Biotech Group (USA), Inc~~2. ~~(the “Company”).~~02 ~~Mr.~~Results ~~Balloch was a member~~ of ~~the~~Operations ~~Audit Committee of the Board of Directors of the Company. There were no disagreements between Mr. Balloch~~ and ~~the Company~~Financial ~~on any matter relating to the Company’s operations, policies or practices, which resulted in his resignation~~Condition.

~~Mr. Balloch’s~~On ~~resignation~~March ~~letter~~31, ~~dated~~2011, asTiens ofBiotech Group (USA), Inc. issued a press release announcing its financial results for the fiscal year ended December 2131, 2010,. The full text of the press release is set forth in Exhibit 99.1 attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description	~~Description~~
99.1	Press Release, dated March 31, 2011.	~~Resignation Letter of Howard Balloch, dated December 21, 2010.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIENS BIOTECH GROUP (USA), INC.
Date: January 4, 2011	By:	/s/ Jinyuan Li
Date: March 31, 2011	By: /s/ Jinyuan Li
	Name: Jinyuan Li	~~Name: Jinyuan Li~~
	Title: Chief Executive Officer	~~Title: Chief Executive Officer~~

~~Exhibit Index~~Exhibits

Exhibit Number	Description	~~Description~~
99.1	Press Release, dated March 31, 2011.	~~Resignation Letter of Howard Balloch, dated December 21, 2010.~~

Filing Compare · TIENS BIOTECH GROUP USA INC